Prophylactic Regimen of Intravenous Oxytocin, Intravenous Tranexamic Acid, and Intramuscular Ergot Derivative for Primary Prevention of Postpartum Hemorrhage in Intrapartum Cesarean Section Versus Intravenous Carbetocin Alone

What Was Tested

In this not phased trial, researchers set out to test Oxytocin and Carbetocin.

It had two arms (groups): Group A (experimental) and Group B (active comparator).

The registry classes the interventions as drug.

Who Took Part

80 planned participants were the target.

It was open to women only aged from 18 years up to 45 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Women undergoing C-Sections. Women between the ages of 18 and 45 years. Gestational age is equal to or more than 36 weeks. No known coagulopathy or bleeding disorders. No known hypersensitivity or allergy to drugs used in the study.

The full record lists 7 inclusion and 8 exclusion criteria; among the exclusions: hemodynamically unstable or immobile patients; multifetal pregnancy; patients who are receiving prophylactic or therapeutic anticoagulation.

How the Study Was Run

The set-up was randomized, parallel-group and double-blind.

Because people in this Oxytocin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Neither the participants nor the staff measuring them knew who was on Oxytocin, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant and investigator.

It started in 2026-01-01 with completion listed for 2026-06-30.

Its stated primary purpose is prevention.

What Was Measured

Primary outcome: Amount of blood loss (time frame: during and up to 24 hours after cesarean section).

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Oxytocin and Carbetocin in 80 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Oxytocin compound page and the Carbetocin compound page, all human trials.